Page last updated: 2024-12-06

setipafant

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Setipafant: platelet activating factor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65968
CHEMBL ID2107078
SCHEMBL ID2110462
MeSH IDM0545453

Synonyms (19)

Synonym
4h-pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8h)-carboxamide, 7,10-dihydro-6-(2-chlorophenyl)-n-(4-methoxyphenyl)-1-methyl-
setipafant [inn]
bn 50727
6-(o-chlorophenyl)-7,10-dihydro-1-methyl-4h-pyrido(4',3':4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8h)-carbox-p-anisidide
setipafant
unii-ufn2q54hs6
132418-35-0
ufn2q54hs6 ,
CHEMBL2107078
SCHEMBL2110462
DTXSID90157552
CS-6678
HY-101675
bn50727
6-(2-chlorophenyl)-n-(4-methoxyphenyl)-1-methyl-7,10-dihydro-4h-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8h)-carboxamide
bn-50727; lau-0901
Q27291060
9-(2-chlorophenyl)-n-(4-methoxyphenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene-14-carboxamide
AKOS040742627
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's18 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.56%)5.53%
Reviews4 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (72.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]